Skye Bioscience Provides 2025 Look Ahead and Year in Review
Provided By GlobeNewswire
Last update: Jan 13, 2025
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health, enters 2025 positioned to announce Phase 2 data for nimacimab, a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential to enhance important facets of obesity treatment while achieving significant weight loss. Skye’s goal in 2025 is to achieve clinical milestones and new scientific insights related to the unique effects and metabolic mechanisms of peripheral CB1 inhibition.
Read more at globenewswire.com1.57
+0.14 (+9.79%)
Find more stocks in the Stock Screener
SKYE Latest News and Analysis
6 days ago - ChartmillTop stock movements in today's session.Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
